April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Oral azithromycin versus doxycyclin for the treatment of moderate to severe meibomian gland dysfunction (MGD): a randomized prospective non-inferiority study.
Author Affiliations & Notes
  • Antoine Heitz
    NOUVEL HOPITAL CIVIL DE STRASBOURG, Strasbourg, France
  • Sauer Arnaud
    NOUVEL HOPITAL CIVIL DE STRASBOURG, Strasbourg, France
  • Carine Merklen
    NOUVEL HOPITAL CIVIL DE STRASBOURG, Strasbourg, France
  • Bernard Cribier
    NOUVEL HOPITAL CIVIL DE STRASBOURG, Strasbourg, France
  • Claude Speeg-Schatz
    NOUVEL HOPITAL CIVIL DE STRASBOURG, Strasbourg, France
  • Tristan Bourcier
    NOUVEL HOPITAL CIVIL DE STRASBOURG, Strasbourg, France
  • Footnotes
    Commercial Relationships Antoine Heitz, None; Sauer Arnaud, None; Carine Merklen, None; Bernard Cribier, None; Claude Speeg-Schatz, None; Tristan Bourcier, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1481. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Antoine Heitz, Sauer Arnaud, Carine Merklen, Bernard Cribier, Claude Speeg-Schatz, Tristan Bourcier; Oral azithromycin versus doxycyclin for the treatment of moderate to severe meibomian gland dysfunction (MGD): a randomized prospective non-inferiority study.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1481.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The main purpose of this study was to evaluate the clinical efficiency and safety of oral azithromycin versus oral doxycyclin in the treatment of subjects with moderate to severe MGD. We were also able to evaluate rosacea prevalence for the trial population.

Methods: Patients with moderate to severe MGD (n=95) were randomized to receive oral azithromycin 500 mg three times a week tapered for 3 months (n=49) or oral doxycyclin 100mg daily for 3 months (n=46). Primary outcome measures were palpebral signs and dermatologic signs of rosacea. Secondary measures were quality of life, Tear film Break Up Time, corneal staining, tolerance and compliance. Statistical analysis was performed using Mann-Whitney-Wilcoxon tests.

Results: Azithromycin showed statistically significant non-inferiority for all endpoints as compared to doxycycline. Excellent tolerance was observed with only 5% percent occurrence of side effects in both groups. Compliance was good with 7% of non-compliant patients in both groups.

Conclusions: Oral azithromycin seems to be an excellent alternative to oral doxycyclin in patients with moderate to severe MGD.

Keywords: 526 eyelid • 486 cornea: tears/tear film/dry eye • 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×